By. Filippo Pietrantonio, MD Date: 11/14/2023 Clinical data from the study demonstrated the inhibition of feedback reactivation pathways with an accumulation of activated GFR, providing a compelling rationale for combining Sotorasib with an anti-EGFR monoclonal antibody. Dr. Pietrantonio, MD, emphasized the need to enhance outcomes beyond monotherapy. The CodeBreak 300 trial, a global and phase … Continue reading Sotorasib + Panitumumab in KRAS G12C CodeBreak 300 Phase 3 Trial